JPRN-jRCT2080221553未知1 期
A Phase I Study of weekly ABI-007 in Combination with TS-1 in Patients with Metastatic Breast Cancer
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- Female
入选标准
- •Patient has no prior chemotherapy or one for metastatic breast cancer. No prior chemotherapy of Taxanes or TS-1 for metastatic breast caner.
- •- Patient has no over-expressed HER2 for IHC or FISH.
排除标准
- •- Patient has recurrent disease within 12 months following the end of neo-adjuvant or adjuvant chemotherapy with a Taxane-containing regimen.
研究者
相似试验
进行中（未招募）
1 期
Efficacy of ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.metastatic pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2013-001463-23-FRGERCOR114
已完成
1 期
Phase I clinical study of ABI-007 in combination with gemcitabinepancreatic cancerJPRN-jRCT2080223124Taiho Pharmaceutical Co., Ltd.40
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic adenocarcinoma of the pancreasMedDRA version: 14.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ITABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATIO842
进行中（未招募）
1 期
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ESAbraxis BioScience, LLC, an indirect subsidiary of Celgene Corporation842
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2009-011305-17-DEAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation842